NewAmsterdam Pharma Co N.V (NAMS) Current Deferred Revenue: 2022-2025
Historic Current Deferred Revenue for NewAmsterdam Pharma Co N.V (NAMS) over the last 1 years, with Mar 2025 value amounting to $3.0 million.
- NewAmsterdam Pharma Co N.V's Current Deferred Revenue fell 62.67% to $3.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.0 million, marking a year-over-year decrease of 62.67%. This contributed to the annual value of $6.0 million for FY2024, which is 39.68% down from last year.
- Per NewAmsterdam Pharma Co N.V's latest filing, its Current Deferred Revenue stood at $3.0 million for Q1 2025, which was down 49.57% from $6.0 million recorded in Q4 2024.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Current Deferred Revenue registered a high of $18.7 million during Q4 2022, and its lowest value of $3.0 million during Q1 2025.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's median Current Deferred Revenue value was $6.0 million (recorded in 2024), while the average stood at $6.3 million.
- Data for NewAmsterdam Pharma Co N.V's Current Deferred Revenue shows a maximum YoY crashed of 62.67% (in 2025) over the last 5 years.
- Over the past 4 years, NewAmsterdam Pharma Co N.V's Current Deferred Revenue (Quarterly) stood at $18.7 million in 2022, then crashed by 46.64% to $10.0 million in 2023, then plummeted by 39.68% to $6.0 million in 2024, then plummeted by 62.67% to $3.0 million in 2025.
- Its Current Deferred Revenue was $3.0 million in Q1 2025, compared to $6.0 million in Q4 2024 and $4.5 million in Q3 2024.